.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,217,895

« Back to Dashboard

Claims for Patent: 6,217,895

Title: Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Abstract:The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
Inventor(s): Guo; Hong (Belmont, MA), Ashton; Paul (Boston, MA)
Assignee: Control Delivery Systems (Watertown, MA)
Application Number:09/273,548
Patent Claims: 1. A method for administering a corticosteroid to a posterior segment of an eye, the method comprising the step of:

implanting a sustained release device to deliver the corticosteroid to the vitreous of the eye and wherein aqueous corticosteroid concentration is less than vitreous corticosteroid concentration during release.

2. A method according to claim 1, wherein aqueous corticosteroid concentration is about 0.002 .mu.g/ml to about 0.01 .mu.g/ml.

3. A method according to claim 2, wherein aqueous corticosteroid concentration is about 0.01 .mu.g/ml to about 0.05 .mu.g/ml.

4. A method according to claim 1, wherein aqueous corticosteroid concentration is non-toxic and is less than 0.05 .mu.g/ml.

5. A method according to claim 1, wherein the device releases corticosteroid for about 1 month to about 20 years.

6. A method according to claim 5, wherein the device releases corticosteroid for about 6 months to about 5 years.

7. A method according to claim 1, wherein the vitreous corticosteroid concentration is therapeutic.

8. A method according to claim 1, wherein the vitreous corticosteroid concentration is less than about 10 .mu.g/ml.

9. A method according to claim 1, wherein the corticosteroid is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

10. A method according to claim 1, comprising intravitreally implanting the sustained release device.

11. A method according to claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

12. A method according to claim 1, wherein the sustained release device releases the corticosteroid with pseudo zero order kinetics.

13. A method according to claim 1, wherein the sustained release device has a mean release rate of about 1 .mu.g/day to about 50 .mu.g/day of corticosteroid.

14. A method according to claim 13, wherein sustained release device has a mean release rate of about 1 .mu.g/day to about 10 .mu.g/day of corticosteroid.

15. A method according to claim 1, wherein the sustained release device releases only one drug.

16. An implantable, sustained release device for administering a corticosteroid to a posterior segment of an eye, the device comprising:

a corticosteroid, wherein the device is configured to provide sustained release of the corticosteroid to the vitreous of the eye such that aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during the release.

17. A device according to claim 16, wherein the device is configured to provide sustained release of the corticosteroid to the vitreous of the eye such that aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during the release.

18. A device according to claim 16, wherein the corticosteroid is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

19. A device according to claim 16, wherein the sustained release device releases the corticosteroid with pseudo zero order kinetics.

20. A device according to claim 16, wherein the sustained release device has a mean release rate of about 1 .mu.g/day to about 50 .mu.g/day of corticosteroid.

21. A device according to claim 16, wherein the sustained release device releases only one drug.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc